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BACKGROUND AND AIMS: Drugs used to treat patients with ulcerative colitis (UC)
are not always effective because of non-specific distribution, metabolism in gastrointestinal tract, and side effects. We designed a nitroxide radical-containing nanoparticle (RNP O ) that accumulates specifically in the colon to suppress inflammation and reduce the undesirable side effects of nitroxide radicals. Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affects millions of patients worldwide. 1 -4 Since the etiology and pathogenesis of IBD are not well understood, it is considered an intractable disease. The intestinal mucosa of patients with IBD is characterized by reactive oxygen species (ROS) overproduction and an imbalance of important antioxidants, leading to oxidative damage. Self-sustaining cycles of oxidant production may amplify inflammation and mucosal injury. [5] [6] [7] [8] In several experimental models, antioxidant compounds and free radical scavengers have improved colitis. [9] [10] [11] Nanoparticles such as liposome and polymeric micelles have gained worldwide attention as a new medical technology, because they change biodistribution of drugs to result in therapeutic effect of drugs significantly.
METHODS: RNP
However, these compounds are not completely effective due to a non-specific drug distribution, a low retention in the colon and side effects. If antioxidant compounds are specifically targeted to the diseased sites and effectively scavenge excessive generated ROS, they represent a safe and effective treatment for IBD. 12, 13 In particular, the intratumoral microdistribution of nanoparticle has been studied for over two decades that nanoparticles can accumulate in sites of tumor due to the increased vascular permeability. 14 -17 Recently, we have developed an amphiphilic block copolymer, poly(ethylene glycol)-b-poly[p-4-(2,2,6,6-tetramethylpiperidine-1-oxyl)aminomethylstyrene] (PEG-b-PMNT), possessing stable nitroxide radicals in the hydrophobic segment as a side chain via an amine linkage, which forms core-shell-type micelles in the physiological environment with an average diameter of about 40 nm, and termed nitroxide radical-containing nanoparticle (RNP N ). 18 Nitroxide radicals are confined in the core of this micelle, which shows high biocompatibility, including long-term blood circulation when administered intravenously and low toxicity. Therefore, RNP N has been studied for therapy in oxidative stress injuries 18 -22 and bioimaging. 23, 24 In this study, we describe a novel nanotherapy for the treatment of UC via oral administration. In order to target the nanoparticle to the colon area, its accumulation in the colonic mucosa is optimized, preventing its uptake into the bloodstream. We For example, pH-sensitive RNP N works effectively in acute renal injury 18 and cerebral ischemia-reperfusion 19 because it disintegrates in acidic conditions of diseased area by protonation of amino groups. However, pH-disintegrative character is not suitable for the treatment of UC via oral administration.
(MeO-PEG-b-PMOT), which is an amphiphilic block copolymer with stable nitroxide radicals in a hydrophobic segment as a side chain via an ether linkage and forms 40-nm-diameter core-shell-type micelles (RNP O ) by self-assembly in the aqueous environments regardless of pH ( Figure 1A ). Here, we investigate specific accumulation into bloodstream and has an extremely high therapeutic efficiency in mice with DSS-induced colitis ( Figure 1B ).
Materials and Methods

Preparation of RNP O
RNP O was prepared by a self-assembling MeO-PEG-b-PMOT block copolymer, as previously reported. 18 Briefly 
Preparation of rhodamine-labeled RNP O , 125 I-labeled RNP O , polystyrene latex particles with nitroxide radicals
Detailed methods were described in Supplementary Materials and Methods section.
Animals
All experiments were carried out using 7-week-old male ICR mice (32-35 g) purchased from Charles River Japan, Inc. Mice were maintained in the experimental animal facilities at the University of Tsukuba. All experiments were performed according to the Guide for the Care and Use of Laboratory Animals at the University of Tsukuba. and 24 hours after oral administration. The major digestive organs (small intestine, cecum, and colon) and blood were isolated, and their radioactivities were measured by a γ-counter (ARC-380, Aloka, Japan). The percentage of radioactivity in each organ was determined based on the initial total radioactivity. 
Localization of RNP O in the colon
Induction of colitis by DSS and drug administration
Evaluation of colitis severity by disease activity index (DAI) and colon length;
Histological assessment; Measurements of myeloperoxidase (MPO) activity, interleukin (IL)-1 β and superoxide production
Intravital observation by in vivo live imaging
Aqueous solution of DSS (3% wt/vol) was administered by free access for 7 days to induce colitis in mice. One mL of RNP O (10 mg/mL) was orally administered daily. After 7 days of treatment, mice were anesthetized with urethane (15 g/kg, Sigma-Aldrich) and an arc-shaped incision was made in the peritoneum to expose the colon. Then, approximately 1 cm length incision was made to observe the colonic mucosa and the remained contents in the colon were removed gently by physiological saline. Mice were set on the stage of microscope and in vivo live imaging was acquired after 2 hours with a microscope. Dead cells in colonic mucosa were identified by staining of propidium iodide in physiological buffer (50 μg/mL; Wako Pure Chemicals)
under an excitation wavelength of 488 nm and an emission wavelength of 515 nm.
Survival rate experiment
The survival rate of mice was determined by replacing drinking water with a 3% (wt/vol) solution of DSS for 15 days. Starting on day 5, drugs were oral administered daily until day 15, and the number of surviving mice was counted until day 15.
Statistical analysis
All values are expressed as mean ± standard error of mean (SEM). Differences between groups were examined for statistical significance using the one-way and two-way ANOVA, followed by Bonferroni post-hoc test (SPSS  software, IBM Corp., NY, USA). A P-value < .05 was considered significant for all statistical analyses.
Results
Specific accumulation of RNP O in colonic mucosa and inflamed colon area
The accumulation of nanoparticles in the colon area is one of the most important features for an effective nanomedicine against UC. Firstly, we orally administered fluorescently labeled nanoparticles, and analyzed the accumulation of these In order to quantify the accumulation of nanoparticles in the colon area, we compared RNP O with different sizes of commercial available polystyrene latex particles and low-molecular-weight compound, TEMPOL. Because we introduced nitroxide radicals into the particles, their accumulation could be quantitatively monitored by electron spin resonance (ESR) measurements. When we orally administered low-molecular-weight TEMPOL to mice, almost no ESR signal was observed in the colon, as shown in Figure 2B . In contrast, polystyrene latex particles showed a higher accumulation in the colon compared to low-molecular-weight TEMPOL. From these results, the size-dependent accumulation in colon was observed. Polystyrene latex particles with 40 nm and 100 nm in size accumulated higher than large-sized particles (0.5 µm and 1 µm), which is consistent with previous reports. 25, 26 Next, we investigated the specific accumulation of RNP O in the injured colon. ( Figure 2C ). This result suggested that RNP O accumulates to a greater extent in inflammatory sites, such as in UC.
Distribution and non-absorption into bloodstream of RNP O after oral administration
As previously mentioned, we confirmed the specific accumulation of RNP O in the DSS-injured colon. It is also important to estimate the non-specific distribution in whole body. Therefore, to precisely evaluate non-specific distribution, we used radioisotope 125 I-labeled RNP O (see Supplementary Materials and Methods), which moved from the small intestine, to the cecum, and to the colon over time after oral administration ( Figure 3A) . Specifically, in the first hour after administration, 3.2% of the initial dose of RNP O had reached the colon. It accumulated to a maximum of 14.5%
of the initial dose 4 hours after administration. Twenty-four hours after administration, there was 0.5% of the initial dose of RNP O remaining in the colon. Importantly, we did not observe the uptake of RNP O into the bloodstream ( Figure 3A ). This is in sharp contrast to low-molecular-weight compounds, such as TEMPOL. This difference in bloodstream uptake via the gastrointestinal tract (GIT) was further confirmed by ESR measurements. Low-molecular-weight TEMPOL was absorbed into the bloodstream through the GIT in normal mice and even more in DSS-treated mice ( Figure 3B ).
However, when RNP O was administered orally, there was no observable ESR signal in the blood, which was consistent with the results from the experiments of 125 I-labeled RNP O . In the present study, oral nanotherapy with RNP O prevented uptake into the bloodstream, suggesting a lack of systemic side effects.
Stability of RNP O in GIT
Next, we evaluated the stability of orally administered RNP O in the GIT using ESR spectra of RNP O in the colon. The ESR signals of low-molecular-weight TEMPOL in the colon showed a sharp triplet due to an interaction between the 14 N nuclei and the unpaired electron, as previously reported 18 (Figure 3B , inset, grey spectrum). In contrast, the ESR signals of RNP O in the colon were broad ( Figure 3B , inset, black spectrum),
suggesting that RNP O remains as core-shell type micelle even in the GIT. The stability of self-assembled RNP O with several tens of nanometers in GIT could prevent the uptake into the bloodstream through the intestinal wall. After reaching colon, RNP O is accumulated in inflamed and mucosal area, followed by effectively scavenging ROS. It is noted that RNP N , which contains amino group as side chains in the hydrophobic segment, is absorbed into the bloodstream when administered orally (data not shown).
It is likely that the disintegration of RNP N in the stomach facilitates its uptake into the bloodstream through the intestinal wall, which was not observed in RNP O .
Therapeutic effect of RNP O on DSS-induced colitis in mice
Since orally administered RNP O accumulated in the colonic mucosa of DSS-injured mice and was not absorbed into the bloodstream, it is anticipated to be an ideal nanomedicine for UC treatment. Therefore, we investigated its therapeutic and suppressive effects on DSS-induced colitis model in mice. RNP O was orally administered daily to DSS-injured mice for 7 days. Additional DSS-injured mice were treated with low-molecular-weight TEMPOL, commercially anti-ulcer mesalamine and micelle without nitroxide radicals as controls. After 7 days of treatment, we assessed the severity of colitis on the basis of DAI 27 (see Supplementary Table 1 ), colon length, and histological analysis. Mice treated with DSS had a significant increase in DAI and shortening of the colon compared to control mice ( Figure 4A,B) . The treatments with low-molecular-weight TEMPOL or mesalamine showed efficiency to decrease DAI as compared to DSS-treated mice, though this efficiency was not significant. On the contrary, RNP O -treated mice showed much lower DAI and preserved colon length compared to DSS-treated mice (P < .01) and other low-molecular-weight drugs-treated mice. It should be noted that no effect was observed when polymeric micelle without nitroxide radicals was administered instead of RNP O . Additionally, histological analyses showed that mucosal structures of DSS-and micelle-treated mice were significantly damaged, viz., destruction of crypts and high levels of neutrophil invasion were observed in these mice. Low-molecular-weight TEMPOL-or mesalamine-treated mice showed moderately damaged mucosal structures. Contrary of those treatments, RNP O -treated mice showed almost similar to that of control mice ( Figure 4C Figure 5A ).
Low-molecular-weight TEMPOL and mesalamine showed the effect to suppress white blood cells in DSS-treated mice; however, the significance was not observed.
Furthermore, results of the hematological analysis indicated higher levels of red blood cells and hemoglobin in the blood of RNP O -treated mice (Figure 5B,C) . This suggests that the intestinal wall was protected from hemorrhage in RNP O -treated mice. We further investigated the desquamation of impaired epithelial cells and cell death in colonic mucosa by intravital observation using in vivo microscopic live imaging and propidium iodide staining. 28 The results showed that a great number of desquamated cells and cell death existed in colonic mucosa of DSS-treated mice ( Figure 5D , Supplementary Video 1). In contrast, in colonic mucosa of RNP O -treated mice, the desquamation and cell death was remarkably suppressed. On the basis of these results, it was confirmed that the colonic injury is protected by the oral administration of RNP O .
RNP O suppresses pro-inflammatory mediators and enhances survival rate in mice
In addition, after 7 days of treatment, we determined pro-inflammatory mediators in the colonic mucosa, including MPO activity, IL-1β and superoxide. These pro-inflammatory mediators are well-known markers of inflammation and play an important role in UC. Low-molecular-weight TEMPOL and mesalamine did not effectively suppress these pro-inflammatory mediators induced by DSS ( Figure 6A-C) . Figure 6D ). On the other hand, RNP O treatment significantly increased the survival rate of DSS-treated mice to 83.3%. This indicates that RNP O has not only suppressive but also therapeutic effects on mice with DSS-induced colitis.
Discussion
Despite significant advances in treatments, IBD remains a major clinical problem, because no drug is entirely effective. For many years, there were only 2 treatment options for IBD: corticosteroids and mesalamine. 29, 30 Although they are effective in treating IBD in some extent, their severe side effects have raised significant concerns among both physicians and patients, and limited their use. In addition, anti-TNF-α antibody is employed to suppress inflammation of UC, which works well though it is cost-oriented therapy with multiple side effects. 31 Recently, many promising low-molecular-weight medications, such as antioxidants, have been found beneficial in experimental models of UC. [9] [10] [11] 32 Unfortunately, results of clinical trials investigating these promising drugs have been largely negative. The drawbacks of current low-molecular-weight drugs are poor stability in stomach, low solubility and side effects on whole body when they enter the bloodstream. In this study, we have developed a novel nitroxide radical-containing nanoparticle RNP O that accumulates specifically in colon area to suppress the inflammation in DSS-induced colitis mice. For UC treatment via oral administration, this nanoparticle showed excellent properties, including high accumulation in inflamed tissues of colon and non-absorption into the bloodstream.
Here, we found that the accumulation in colon area depends on the sizes and PEGylated character of particles. Both low-molecular-weight drugs, submicron-and micron-sized polystyrene latex particles showed poor accumulation in colon, whereas higher accumulation of particles with approximately several tens of nanometers was observed. Optimal size of several tens of nanometers allowed easier diffusion in the mucosa compared to larger sized particles. 25, 26, 33 In addition, 40-nm-diameter RNP O with PEG shell showed significantly high accumulation and long retention in colon area compared to polystyrene latex particles with similar size of 40 nm. PEGylated character of RNP O might protect nitroxide radicals in the hydrophobic core from hash conditions of GIT after oral administration, resulting in the significant accumulation in colon area. 34 Furthermore, PEG chains of RNP O may achieve mucoadhesion due to their ability to inter-diffuse among the mucus network and polymer entanglement with mucin, which is composed of glycoprotein. 35 Therefore, PEGylated character of RNP O showed much significant effect on its accumulation in colonic mucosa. Eventually, we observed the accumulation of RNP O in colon is almost 50 times higher than that of low-molecular-weight TEMPOL. To deliver sufficient dose of anti-inflammatory drugs for UC treatment, high dose of drugs is required, however it leads to undesirable side effects, because almost all low-molecular-weight drugs tend to metabolize in upper GIT or absorb into bloodstream. 36, 37 In case of RNP O , no absorption into bloodstream was observed via oral administration route, which improves accumulation in colon region and prevents side effects to whole body. Another interesting phenomenon in our study is the higher accumulation of nanoparticles in inflammatory colon than healthy colon.
Mucus layer in colon area is significantly thicker than that in small intestine, which is considered as a significant barrier to nanoparticle penetration. 38 In colon of patients with UC, the overall thickness of the adherent mucus layer is reduced due to the reduction of goblet cells, 38, 39 resulting in the facile penetration of nanoparticles in inflammatory tissues. In addition, the opening tight junction of epithelium cells in UC is another explanation for higher accumulation of nanoparticles. 40 After In conclusion, we have developed a novel nitroxide radical-containing nanoparticle, RNP O , which possesses anti-oxidative nitroxide radicals in the core for treatment of DSS-induced colitis mice. RNP O significantly accumulated not only in the mucosa but also higher in inflammatory sites of the colon, resulting in a high therapeutic effect, which was not observed in low-molecular-weight drugs. In addition, RNP O may lack the undesirable side effects of low-molecular-weight TEMPOL, since it is not absorbed into the bloodstream. Our results indicated that the therapeutic efficiency of nitroxide radicals could be successfully enhanced by using nanoparticles to suppress inflammation in the colon area and reduce undesirable side effects.
Therefore, we believe that RNP O may become an important therapeutic agent for the treatment of UC. 
